The US Patent and Trademark Office (USPTO) has granted SmartInhaler maker Adherium Limited US Patent No. 9,468,729, titled “Releasable monitor with optical dose counter for a medicament inhaler, the company announced, saying that, “This patent confirms Adherium’s ongoing commitment to innovation in the medication adherence market.”
According to Adherium, the company is seeking additional patents for monitoring devices that include optical dose counters.
Adherium Group CEO Garth Sutherland commented, “Adherium is committed to improving patient health outcomes through accurate medication monitoring and invests significant effort and resources into Research & Development to achieve this objective. As a result, Adherium intends to diligently assert its intellectual property rights.”
In July 2017, the company announced a partnership with AstraZeneca to provide monitoring devices for asthma and COPD patient support programs, and AstraZeneca is using Adherium’s SmartInhaler technology in a COPD medication adherence study.
Read the Adherium press release.
